Skip to search formSkip to main contentSkip to account menu

17-allylamino-17-demethoxygeldanamycin hydroquinone

Known as: 17-allylamino-17-demethoxygeldanamycin hydroquinone salt, Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-, RETASPIMYCIN 
A small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. Retaspimycin binds to and inhibits… 
National Institutes of Health

Related topics

Related topics

4 relations
HSP90 Heat-Shock ProteinsSignal Transduction Inhibitionretaspimycin hydrochloride

Broader (1)

tanespimycin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
IJPRBS 376
  • Bharat
  • 2013
  • Corpus ID: 212543702
Heat shock protein stabilizing of various oncogenic client proteins to their active conformations that makes it promising anti… 
2013
2013
Abstract 3433: Deciphering the mechanism of synergy between the Heat Shock Protein 90 inhibitor retaspimycin HCl and docetaxel in preclinical models of non-small cell lung cancer.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Heat Shock Protein 90 (Hsp90) has emerged as an… 
2012
2012
The heat shock protein 90 inhibitor SNX-2112 inhibits B 16 melanoma cell growth in vitro and in vivo
SNX-2112 is a selective heat shock protein 90 (Hsp90) inhibitor which can exert a potent anticancer activity. In this study, we… 
2011
2011
Abstract 2827: Activity of the proprietary Hsp90 inhibitor IPI-493 in models of colorectal cancer correlates with RAS pathway activation
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Heat shock protein 90 (Hsp90) plays a role in… 
2011
2011
Abstract 1601: Hsp90 inhibition results in a significant delay in tumor progression in a model of emerging EGFR TKI resistance in non-small cell lung cancer
Heat shock protein 90 (Hsp90) plays a role in regulating the stability of key cancer-causing proteins through its role as a… 
2010
2010
Gateways to clinical trials.
(-)-Epigallocatechin gallate, Abafungin, ACE-031, Adapalene/benzoyl peroxide, AE-37, Aflibercept, AGS-003, Albiglutide… 
2009
2009
A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel.
3547 Background: IPI-504 is a water-soluble heat shock protein 90 (Hsp90) inhibitor. IPI-504 causes the degradation of a variety…